White Paper

Digital Endpoint Resource Guide: Neuromuscular Disorders

Source: ActiGraph

Developing drugs for neuromuscular disorders (NMDs) presents challenges due to suboptimal clinical endpoints for gauging efficacy. Regulatory and payer demands for patient-centered outcomes are rising. Sensor-based digital health technologies (DHTs) offer direct, objective daily life assessments, accelerating NMD drug development.

NMDs like ALS, DMD, and SMA are rare and marked by muscle weakness, significantly impairing daily activities. Traditional clinical assessments suffer from subjectivity and bias, causing longitudinal variability. Wearable DHTs provide continuous, objective function assessment, overcoming travel barriers for NMD patients in clinical trials. They serve as ideal functional endpoints in long-term trials or follow-ups, enabling remote data collection with minimal patient burden.

Learn more about how wearable DHTs offer both continuous, objective assessment of patient function in their natural environment, facilitating the detection of clinically significant effects, and reducing the need for patients with NMDs to travel to clinical sites, a major obstacle to study participation.

access the White Paper!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Clinical Leader? Subscribe today.

Subscribe to Clinical Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Clinical Leader